Corticotropin-Releasing Hormone

PreclinicalSmall molecule

Corticotropin-Releasing Hormone is one of 25 small molecule programs targeting Cocaine Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cocaine DependenceActive, not recruiting

Cocaine DependencePreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Cocaine Dependence

#DrugCompanyPhaseTrials

Keppra

Epidiolex

Namenda

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 5

Prometrium

Ferring

Approved

1 6

Dilantin

VViatris Specialty LLC

Mifeprex

Normodyne

Nimotop

AAzurity Pharmaceuticals

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cocaine Dependence1 trial

Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence

Completed·CCentre for Addiction and Mental Health··NCT01984177·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Corticotropin-Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Corticotropin-Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Corticotropin-Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre for Addiction and Mental Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCentre for Addiction and Mental Health

Corticotropin-Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Dependence1 trial

References

Drug Info

Quick Facts

Related News